Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti‐TNF‐like weak inducer of apoptosis (anti‐TWEAK) monoclonal antibody

Por Galluppi, Gerald R., Wisniacki, Nicolas, Stebbins, Chris
Publicado no Br J Clin Pharmacol (2016)

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

Por von Mehren, Margaret, Britten, Carolyn D., Pieslor, Peter, Saville, Wayne, Vassos, Artemios, Harris, Sarah, Galluppi, Gerald R., Darif, Mohamed, Wainberg, Zev A., Cohen, Roger B., Leong, Stephen
Publicado em 2014